What Carisma Therapeutics Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Klichinsky Michael | Chief Scientific Officer | Oct 07 | Open-market sale · S | −56,982 | $0.25 | −$14.5K | 0 |
| Klichinsky Michael | Chief Scientific Officer | Oct 07 | Exercise / conversion · M | +56,982 | $0.11 | +$6.27K | 56,982 |
| Klichinsky Michael | Chief Scientific Officer | Oct 03 | Open-market sale · S | −119,347 | $0.26 | −$31.1K | 0 |
| Klichinsky Michael | Chief Scientific Officer | Oct 02 | Open-market sale · S | −200,000 | $0.25 | −$50.9K | 119,347 |
| Klichinsky Michael | Chief Scientific Officer | Oct 01 | Open-market sale · S | −165,000 | $0.26 | −$42.4K | 319,347 |
| Torok Michael | Director | Mar 07 | Grant / award · A | +50,000 | — | — | 50,000 |
| Torok Michael | Director | Mar 07 | Grant / award · A | +319,991 | — | — | 319,991 |
| Torok Michael | Director | Mar 07 | Grant / award · A | +51,250 | — | — | 51,250 |
| Klichinsky Michael | Chief Scientific Officer | Mar 07 | Grant / award · A | +484,347 | — | — | 484,347 |
| Hodits Regina | Director | Mar 07 | Grant / award · A | +2,297,546 | — | — | 2,297,546 |
| Morrison Briggs | Director | Mar 07 | Grant / award · A | +12,175 | — | — | 12,175 |
| Zweifach Sanford S | Director | Mar 07 | Grant / award · A | +413 | — | — | 413 |
| Ugwumba Chidozie | Director | Mar 07 | Grant / award · A | +2,215,877 | — | — | 2,215,877 |
| Forbes Monica | Chief Financial Officer | Mar 02 | Open-market sale · S | −98,304 | $0.59 | −$57.7K | 505,664 |
| Forbes Monica | Chief Financial Officer | Mar 02 | Exercise / conversion · M | +180,750 | $0.59 | +$106K | 603,968 |
| Forbes Monica | Chief Financial Officer | Mar 02 | Open-market sale · S | −93,279 | $0.59 | −$54.8K | 423,218 |
| Forbes Monica | Chief Financial Officer | Mar 02 | Exercise / conversion · M | +190,375 | $0.59 | +$112K | 516,497 |
| Forbes Monica | Chief Financial Officer | Mar 02 | Open-market sale · S | −154,266 | $0.59 | −$90.6K | 326,122 |
| Cannell Thomas R | President and CEO | Mar 02 | Open-market sale · S | −278,564 | $0.59 | −$164K | 672,386 |
| Cannell Thomas R | President and CEO | Mar 02 | Exercise / conversion · M | +606,800 | $0.59 | +$356K | 950,950 |
Loading...
